Literature DB >> 17954909

Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis.

Christophe Fraser1, T Déirdre Hollingsworth, Ruth Chapman, Frank de Wolf, William P Hanage.   

Abstract

The natural course of HIV-1 infection is characterized by a high degree of heterogeneity in viral load, not just within patients over time, but also between patients, especially during the asymptomatic stage of infection. Asymptomatic, or set-point, viral load has been shown to correlate with both decreased time to AIDS and increased infectiousness. The aim of this study is to characterize the epidemiological impact of heterogeneity in set-point viral load. By analyzing two cohorts of untreated patients, we quantify the relationships between both viral load and infectiousness and the duration of the asymptomatic infectious period. We find that, because both the duration of infection and infectiousness determine the opportunities for the virus to be transmitted, this suggests a trade-off between these contributions to the overall transmission potential. Some public health implications of variation in set-point viral load are discussed. We observe that set-point viral loads are clustered around those that maximize the transmission potential, and this leads us to hypothesize that HIV-1 could have evolved to optimize its transmissibility, a form of adaptation to the human host population. We discuss how this evolutionary hypothesis can be tested, review the evidence available to date, and highlight directions for future research.

Entities:  

Mesh:

Year:  2007        PMID: 17954909      PMCID: PMC2077275          DOI: 10.1073/pnas.0708559104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Imperfect vaccines and the evolution of pathogen virulence.

Authors:  S Gandon; M J Mackinnon; S Nee; A F Read
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; J Martin Okongo; Rosemary Lubega; James A G Whitworth
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

3.  Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study.

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; James A G Whitworth
Journal:  BMJ       Date:  2002-01-26

4.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

5.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.

Authors:  S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

Review 6.  Recent observations on HIV type-1 infection in the genital tract of men and women.

Authors:  Robert W Coombs; Patricia S Reichelderfer; Alan L Landay
Journal:  AIDS       Date:  2003-03-07       Impact factor: 4.177

7.  Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

Authors:  Guido Silvestri; Donald L Sodora; Richard A Koup; Mirko Paiardini; Shawn P O'Neil; Harold M McClure; Silvija I Staprans; Mark B Feinberg
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

Review 8.  The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.

Authors:  C Fraser; N M Ferguson; F de Wolf; R M Anderson
Journal:  Proc Biol Sci       Date:  2001-10-22       Impact factor: 5.349

9.  Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Authors:  Sarah C Ball; Awet Abraha; Kalonji R Collins; Andre J Marozsan; Heather Baird; Miguel E Quiñones-Mateu; Adam Penn-Nicholson; Michael Murray; Nathalie Richard; Michael Lobritz; Peter A Zimmerman; Tatsuyoshi Kawamura; Andrew Blauvelt; Eric J Arts
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  180 in total

1.  Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention.

Authors:  Audrey Pettifor; Catherine MacPhail; Amy Corneli; Jabu Sibeko; Gift Kamanga; Nora Rosenberg; William C Miller; Irving Hoffman; Helen Rees; Myron S Cohen
Journal:  AIDS Behav       Date:  2011-08

2.  Unrestricted migration favours virulent pathogens in experimental metapopulations: evolutionary genetics of a rapacious life history.

Authors:  Christal M Eshelman; Roxanne Vouk; Jodi L Stewart; Elizabeth Halsne; Haley A Lindsey; Stacy Schneider; Miliyard Gualu; Antony M Dean; Benjamin Kerr
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-08-27       Impact factor: 6.237

Review 3.  The virulence-transmission trade-off in vector-borne plant viruses: a review of (non-)existing studies.

Authors:  R Froissart; J Doumayrou; F Vuillaume; S Alizon; Y Michalakis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

4.  Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland.

Authors:  Helena Skar; Maria Axelsson; Ingela Berggren; Anders Thalme; Katarina Gyllensten; Kirsi Liitsola; Henrikki Brummer-Korvenkontio; Pia Kivelä; Erika Spångberg; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  The effects of a deleterious mutation load on patterns of influenza A/H3N2's antigenic evolution in humans.

Authors:  Katia Koelle; David A Rasmussen
Journal:  Elife       Date:  2015-09-15       Impact factor: 8.140

6.  From within-host interactions to epidemiological competition: a general model for multiple infections.

Authors:  Mircea T Sofonea; Samuel Alizon; Yannis Michalakis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

7.  Drivers of variation in species impacts for a multi-host fungal disease of bats.

Authors:  Kate E Langwig; Winifred F Frick; Joseph R Hoyt; Katy L Parise; Kevin P Drees; Thomas H Kunz; Jeffrey T Foster; A Marm Kilpatrick
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

8.  Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load.

Authors:  Andrew R Wargo; Alison M Kell; Robert J Scott; Gary H Thorgaard; Gael Kurath
Journal:  Virus Res       Date:  2012-01-30       Impact factor: 3.303

9.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.